Evidence map›Paper›PMID 33840521›Full record

ArticleMayo Clinic proceedings2021

Relative Predictive Value of Circulating Immune Markers in US Adults Without Cardiovascular Disease: Implications for Risk Reclassification.

Kartik Gupta, Rajat Kalra, Mike Pate, Shivaraj Nagalli, Sameer Ather, Indranee Rajapreyar, Pankaj Arora, Ankur Gupta, Wunan Zhou, Raul San Jose Estepar and 3 more

Abstract read
In one paragraph

Article in Mayo Clinic proceedings, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kartik GuptaDivision of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL; Division of General Internal Medicine, Henry Ford Hospital, Detroit, MI.
Rajat KalraCardiovascular Division, University of Minnesota, Minneapolis, MN.
Mike PateDivision of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL.
Shivaraj NagalliYuma Regional Medical Center, Yuma, AZ.
Sameer AtherSection of Cardiology, Birmingham Veteran Affairs Medical Center, Birmingham, AL.
Indranee RajapreyarDivision of General Internal Medicine, Henry Ford Hospital, Detroit, MI.
Pankaj AroraDivision of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL; Section of Cardiology, Birmingham Veteran Affairs Medical Center, Birmingham, AL.
Ankur GuptaDivision of Cardiology, Henry Ford Hospital, Detroit, MI.
Wunan ZhouCardiology Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Raul San Jose EsteparDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Marcelo Di CarliCardiovascular Imaging Program, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (M.D.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Sumanth D PrabhuDivision of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL; Section of Cardiology, Birmingham Veteran Affairs Medical Center, Birmingham, AL. Electronic address: sprabhu@uabmc.edu.
Navkaranbir S BajajDivision of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL; Division of Molecular Imaging and Therapeutics, Department of Radiology, University of Alabama at Birmingham, Birmingham, AL; Section of Cardiology, Birmingham Veteran Affairs Medical Center, Birmingham, AL. Electronic address: nbajaj@uabmc.edu.

Funding

National Dissemination of I-Corps@NCATS: Accelerating Translation through CommercializationUL1TR003096 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M, KIMBERLY, ROBERT P. · 2019 to 2023
$43.6M
UAB Center for Clinical and Translational Science (CCTS)UL1TR001417 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2015 to 2018
$31.4M
Macrophage Circadian Clock Disruption and Inflammation in Heart FailureR01HL147549 · NHLBI · WASHINGTON UNIVERSITY · PI PRABHU, SUMANTH D, YOUNG, MARTIN E · 2019 to 2022
$2.3M
Cardiac Macrophages as Disease Drivers in Chronic Ischemic Heart FailureR01HL157999 · NHLBI · WASHINGTON UNIVERSITY · PI PRABHU, SUMANTH D · 2021 to 2024
$2.1M
Splenic Marginal Zone Macrophages in Chronic Ischemic Heart FailureR01HL125735 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PRABHU, SUMANTH D · 2015 to 2018
$1.5M
Role of Regulatory T-Lymphocytes in Chronic Heart FailureI01BX002706 · VA · BIRMINGHAM VA MEDICAL CENTER · PI PRABHU, SUMANTH D · 2015 to 2018
–
BLRD VA I01 BX002706NCATS NIH HHS UL1 TR001417NCATS NIH HHS UL1 TR003096NHLBI NIH HHS R01 HL125735NHLBI NIH HHS R01 HL147549NHLBI NIH HHS R01 HL157999
6 · The paper itself

Abstract

objectiveTo investigate the relative predictive value of circulating immune cell markers for cardiovascular mortality in ambulatory adults without cardiovascular disease.

methodsWe analyzed data of participants enrolled in the National Health and Nutrition Examination Survey from January 1, 1999, to December 31, 2010, with the total leukocyte count within a normal range (4000-11,000 cells/μL [to convert to cells ×10

resultsAmong 21,599 participants eligible for this analysis, the median age was 47 years (interquartile range, 34-63 years); 10,651 (49.2%) participants were women, and 10,713 (49.5%) were self-reported non-Hispanic white. During a median follow-up of 9.6 years (interquartile range, 6.8-13.1 years), there were 627 cardiovascular deaths. MLR had the best predictive value for cardiovascular mortality. The addition of elevated MLR (≥0.3) to the 10-year ASCVD risk score improved the classification by 2.7%±1.4% (P=.04). Elevated MLR had better predictive value than C-reactive protein and several components of the 10-year ASCVD risk score.

conclusionAmong ambulatory US adults without preexisting cardiovascular disease, we found that MLR had the best predictive value for cardiovascular mortality among circulating immune markers. The addition of MLR to the 10-year risk score significantly improved the risk classification of participants.

Indexed as

Cardiovascular DiseasesHeart Disease Risk FactorsAmbulatory CareBiomarkersClassificationC-Reactive ProteinFemaleFollow-Up StudiesHumansLeukocyte CountLymphocytesMaleMiddle AgedMonocytesNeutrophilsPredictive Value of TestsBiomarkersC-Reactive Protein

Identifiers

PMID33840521
PMCPMC8683138

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.